FDA Approves Biotronik’s Thin-Strut Orsiro Coronary Stent
Bioresorbable-polymer, sirolimus-eluting Orsiro outperformed Abbott’s market-leading Xience durable-polymer, everolimus-eluting stent at the two-year follow-up in the BIOFLOW V trial. The company stresses that Orsiro is the first and only ultrathin drug-eluting stent to beat Xience in a randomized trial.
You may also be interested in...
Biotronik’s Orsiro Stent Beats Abbott’s Xience In BIOSTEMI Trial
Acute ST-elevation myocardial infarction patients treated with Biotronik’s Orsiro biodegradable polymer sirolimus-eluting stent had a significantly lower rate of target vessel failure than patients treated with Abbott’s Xience durable polymer everolimus-eluting stent at the one-year follow-up in the BIOSTEMI trial.
Biotronik Rolls Out Biomonitor III Injectable Cardiac Monitor
The company says Biomonitor III documents suspected arrhythmias or unexplained syncope in patients who have experienced cardiac arrhythmias or who are at risk for cardiac arrhythmias.
Results Recap: CRT In DC Features New Biotronik Stent Data, Encouraging TAVR Low-Risk Data; Ablative Systems’ Alcohol Renal Denervation
Medtech Insight's Results Recap covers major device trial results appearing on MedDeviceTracker. This week's edition, covering March 1 to March 7, includes results of late-breaking trials presented at the 2019 Cardiovascular Research Technologies (CRT) conference in Washington, DC, including new data supporting Biotronik’s biodegradable polymer sirolimus-eluting stent and the company’s resorbable magnesium stent, results of the LRT trial of transcatheter aortic valves in low-risk patients, plus promising clinical data supporting Ablative System’s alcohol renal-denervation system.